Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

REFLECTION-An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in Neovascular Age-related Macular Degeneration (nAMD) in a Real-world Setting.

NCT07640997 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT07640997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07640997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
REFLECTION-An Observational Study Program to Investigate the Effectiveness of Aflibercept 8 mg Used in Neovascular Age-related Macular Degeneration (nAMD) in a Real-world Setting.
Lead sponsor
Peking University People's Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 11, 2025
Completion date
December 31, 2027
Enrollment
300 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)